Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-16

AUTHORS

Yasuyuki Shigematsu, Kentaro Inamura, Noriko Yamamoto, Yoshihiro Mise, Akio Saiura, Yuichi Ishikawa, Shunji Takahashi, Hiroaki Kanda

ABSTRACT

BackgroundThe prognostic biomarker for patients undergoing curative liver metastasectomy for colorectal cancer (CRC) is lacking. The purpose was to investigate the prognostic role of a lack of CDX2 expression, which has been proposed as a potential biomarker for high-risk relapse in early-stage CRC, in patients undergoing curative liver metastasectomy.MethodsA total of 396 consecutive patients with CRC liver metastasis who underwent potentially curative liver metastasectomy at a single center in Japan between 2005 and 2015 were included. For the immunohistochemical analysis of nuclear CDX2 expression, we adopted the tissue microarray approach using the resected metastatic liver CRCs. Patient subgroups were compared with respect to disease-free survival (DFS) and overall survival (OS) by applying the Kaplan-Meier curve, log-rank tests, and multivariate analyses based on the Cox proportional hazards method. OS is defined as the period from the date of curative liver resection for metastatic CRC until death. DFS is defined as the length of time from curative liver resection to either the first recurrence or death. In patients without recurrence, the latest imaging inspection date was used as the censored date.ResultsThirty-six of the 396 CRCs (9.1%) reduced CDX2 expression. The reduced expression of CDX2 was associated with poor differentiation (P = 0.02). DFS in days was lower in the patients with CDX2-low CRC than in the patients with CDX2-high CRC (median DFS: 245 days versus 420 days; hazard ratio for disease recurrence: 1.64; 95% confidence interval: 1.08–2.38; P = 0.02). OS in days was lower in the patients with CDX2-low CRC than in the patients with CDX2-high CRC (median OS: 1024 days versus 3145 days; hazard ratio: 2.41; 95% confidence interval: 1.52–3.85; P < 0.001). In patients with CDX2-low CRC, both DFS and OS were similar between the with and without pre- or post-operative chemotherapy groups (median DFS: 243 versus 247 days; P = 0.73, median OS: 1016 versus 1363 days; P = 0.69).ConclusionsReduced expression of CDX2 indicates poor DFS and OS, however, it might not represent chemosensitivity in patients undergoing curative liver metastasectomy. (339/350). More... »

PAGES

980

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-4902-8

DOI

http://dx.doi.org/10.1186/s12885-018-4902-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107664418

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30326864


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CDX2 Transcription Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metastasectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shigematsu", 
        "givenName": "Yasuyuki", 
        "id": "sg:person.0767161400.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767161400.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inamura", 
        "givenName": "Kentaro", 
        "id": "sg:person.0604174351.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604174351.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Noriko", 
        "id": "sg:person.014277231772.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014277231772.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology Center, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410807.a", 
          "name": [
            "Division of Gastroenterology Center, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mise", 
        "givenName": "Yoshihiro", 
        "id": "sg:person.0626665021.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626665021.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Gastroenterology Center, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410807.a", 
          "name": [
            "Division of Gastroenterology Center, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saiura", 
        "givenName": "Akio", 
        "id": "sg:person.0612301703.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612301703.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.486756.e", 
          "name": [
            "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishikawa", 
        "givenName": "Yuichi", 
        "id": "sg:person.01052642300.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052642300.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of General Oncology, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410807.a", 
          "name": [
            "Division of General Oncology, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Shunji", 
        "id": "sg:person.011721243162.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011721243162.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, 362-0806, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416695.9", 
          "name": [
            "Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan", 
            "Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, 362-0806, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanda", 
        "givenName": "Hiroaki", 
        "id": "sg:person.01324616107.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324616107.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1245/s10434-006-9018-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018471158", 
          "https://doi.org/10.1245/s10434-006-9018-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-012-0422-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009676145", 
          "https://doi.org/10.1007/s10147-012-0422-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-003-0833-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013669468", 
          "https://doi.org/10.1007/s00428-003-0833-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-010-0985-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033481932", 
          "https://doi.org/10.1245/s10434-010-0985-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2008.117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048766298", 
          "https://doi.org/10.1038/modpathol.2008.117"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-16", 
    "datePublishedReg": "2018-10-16", 
    "description": "BackgroundThe prognostic biomarker for patients undergoing curative liver metastasectomy for colorectal cancer (CRC) is lacking. The purpose was to investigate the prognostic role of a lack of CDX2 expression, which has been proposed as a potential biomarker for high-risk relapse in early-stage CRC, in patients undergoing curative liver metastasectomy.MethodsA total of 396 consecutive patients with CRC liver metastasis who underwent potentially curative liver metastasectomy at a single center in Japan between 2005 and 2015 were included. For the immunohistochemical analysis of nuclear CDX2 expression, we adopted the tissue microarray approach using the resected metastatic liver CRCs. Patient subgroups were compared with respect to disease-free survival (DFS) and overall survival (OS) by applying the Kaplan-Meier curve, log-rank tests, and multivariate analyses based on the Cox proportional hazards method. OS is defined as the period from the date of curative liver resection for metastatic CRC until death. DFS is defined as the length of time from curative liver resection to either the first recurrence or death. In patients without recurrence, the latest imaging inspection date was used as the censored date.ResultsThirty-six of the 396 CRCs (9.1%) reduced CDX2 expression. The reduced expression of CDX2 was associated with poor differentiation (P\u2009=\u20090.02). DFS in days was lower in the patients with CDX2-low CRC than in the patients with CDX2-high CRC (median DFS: 245\u00a0days versus 420\u00a0days; hazard ratio for disease recurrence: 1.64; 95% confidence interval: 1.08\u20132.38; P\u2009=\u20090.02). OS in days was lower in the patients with CDX2-low CRC than in the patients with CDX2-high CRC (median OS: 1024\u00a0days versus 3145\u00a0days; hazard ratio: 2.41; 95% confidence interval: 1.52\u20133.85; P\u2009<\u2009\u00a00.001). In patients with CDX2-low CRC, both DFS and OS were similar between the with and without pre- or post-operative chemotherapy groups (median DFS: 243 versus 247\u00a0days; P\u2009=\u20090.73, median OS: 1016 versus 1363\u00a0days; P\u2009=\u20090.69).ConclusionsReduced expression of CDX2 indicates poor DFS and OS, however, it might not represent chemosensitivity in patients undergoing curative liver metastasectomy. (339/350).", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-018-4902-8", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5933981", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "disease-free survival", 
      "curative liver resection", 
      "overall survival", 
      "liver metastasectomy", 
      "colorectal cancer", 
      "liver resection", 
      "liver metastases", 
      "CDX2 expression", 
      "colorectal cancer liver metastases", 
      "early-stage colorectal cancer", 
      "poor disease-free survival", 
      "Cox proportional hazards method", 
      "high-risk relapse", 
      "CRC liver metastases", 
      "nuclear CDX2 expression", 
      "metastatic colorectal cancer", 
      "cancer liver metastases", 
      "survival of patients", 
      "Kaplan-Meier curves", 
      "log-rank test", 
      "proportional hazards methods", 
      "tissue microarray approach", 
      "chemotherapy group", 
      "curative resection", 
      "first recurrence", 
      "prognostic role", 
      "consecutive patients", 
      "single center", 
      "ResultsThirty-six", 
      "patient subgroups", 
      "poor differentiation", 
      "prognostic biomarker", 
      "metastasectomy", 
      "immunohistochemical analysis", 
      "hazards methods", 
      "patients", 
      "potential biomarkers", 
      "expression status", 
      "resection", 
      "reduced expression", 
      "length of time", 
      "recurrence", 
      "metastasis", 
      "survival", 
      "biomarkers", 
      "death", 
      "expression", 
      "CDX2", 
      "microarray approach", 
      "days", 
      "relapse", 
      "chemosensitivity", 
      "cancer", 
      "subgroups", 
      "total", 
      "date", 
      "pre", 
      "status", 
      "group", 
      "inspection dates", 
      "differentiation", 
      "period", 
      "center", 
      "role", 
      "lack", 
      "test", 
      "analysis", 
      "purpose", 
      "with", 
      "time", 
      "impact", 
      "Japan", 
      "curves", 
      "length", 
      "method", 
      "respect", 
      "approach"
    ], 
    "name": "Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis", 
    "pagination": "980", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107664418"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-4902-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30326864"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-4902-8", 
      "https://app.dimensions.ai/details/publication/pub.1107664418"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_768.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-018-4902-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4902-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4902-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4902-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4902-8'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      21 PREDICATES      122 URIs      109 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-4902-8 schema:about N2f1f5330e2194b0db5ea732139505921
2 N4f59f382b6a3452fbb7f5f0df8b731b1
3 N62612e52daae439aadd084914c338d0d
4 N653e90f560d247348ca5a189990f317e
5 N72ea159660c448e2874e519436af22b4
6 N7309e7c6dfca4b95979c88e75c45d62c
7 N978942676a7447809a9b65ebcc06b7ec
8 Nb29ff4d3238e4a36b12236fe9da0d3ff
9 Nb5768e82639a4466b6857664220bb0a5
10 Nbb73ec8c407d439a996200495f554b0c
11 Nbd5f936222604af49da011884bbc5f77
12 Nbecb89c64bbe4f3599ef0aabe09eb08a
13 Nca8624a60ffa4e1ba48aa809f2d420ef
14 Ne1677b3f9f344de681651dc0c6a8d0d8
15 Nf6678cc2f03046c5a1eb0177c999a231
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N9e9e9a18b14a44c8bd39a08e9b3e8b13
19 schema:citation sg:pub.10.1007/s00428-003-0833-z
20 sg:pub.10.1007/s10147-012-0422-8
21 sg:pub.10.1038/modpathol.2008.117
22 sg:pub.10.1245/s10434-006-9018-8
23 sg:pub.10.1245/s10434-010-0985-4
24 schema:datePublished 2018-10-16
25 schema:datePublishedReg 2018-10-16
26 schema:description BackgroundThe prognostic biomarker for patients undergoing curative liver metastasectomy for colorectal cancer (CRC) is lacking. The purpose was to investigate the prognostic role of a lack of CDX2 expression, which has been proposed as a potential biomarker for high-risk relapse in early-stage CRC, in patients undergoing curative liver metastasectomy.MethodsA total of 396 consecutive patients with CRC liver metastasis who underwent potentially curative liver metastasectomy at a single center in Japan between 2005 and 2015 were included. For the immunohistochemical analysis of nuclear CDX2 expression, we adopted the tissue microarray approach using the resected metastatic liver CRCs. Patient subgroups were compared with respect to disease-free survival (DFS) and overall survival (OS) by applying the Kaplan-Meier curve, log-rank tests, and multivariate analyses based on the Cox proportional hazards method. OS is defined as the period from the date of curative liver resection for metastatic CRC until death. DFS is defined as the length of time from curative liver resection to either the first recurrence or death. In patients without recurrence, the latest imaging inspection date was used as the censored date.ResultsThirty-six of the 396 CRCs (9.1%) reduced CDX2 expression. The reduced expression of CDX2 was associated with poor differentiation (P = 0.02). DFS in days was lower in the patients with CDX2-low CRC than in the patients with CDX2-high CRC (median DFS: 245 days versus 420 days; hazard ratio for disease recurrence: 1.64; 95% confidence interval: 1.08–2.38; P = 0.02). OS in days was lower in the patients with CDX2-low CRC than in the patients with CDX2-high CRC (median OS: 1024 days versus 3145 days; hazard ratio: 2.41; 95% confidence interval: 1.52–3.85; P <  0.001). In patients with CDX2-low CRC, both DFS and OS were similar between the with and without pre- or post-operative chemotherapy groups (median DFS: 243 versus 247 days; P = 0.73, median OS: 1016 versus 1363 days; P = 0.69).ConclusionsReduced expression of CDX2 indicates poor DFS and OS, however, it might not represent chemosensitivity in patients undergoing curative liver metastasectomy. (339/350).
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N016dd0f355ac4275b768ac623330ebfe
30 Ne570829994a841609a809b1f485461eb
31 sg:journal.1024632
32 schema:keywords CDX2
33 CDX2 expression
34 CRC liver metastases
35 Cox proportional hazards method
36 Japan
37 Kaplan-Meier curves
38 ResultsThirty-six
39 analysis
40 approach
41 biomarkers
42 cancer
43 cancer liver metastases
44 center
45 chemosensitivity
46 chemotherapy group
47 colorectal cancer
48 colorectal cancer liver metastases
49 consecutive patients
50 curative liver resection
51 curative resection
52 curves
53 date
54 days
55 death
56 differentiation
57 disease-free survival
58 early-stage colorectal cancer
59 expression
60 expression status
61 first recurrence
62 group
63 hazards methods
64 high-risk relapse
65 immunohistochemical analysis
66 impact
67 inspection dates
68 lack
69 length
70 length of time
71 liver metastasectomy
72 liver metastases
73 liver resection
74 log-rank test
75 metastasectomy
76 metastasis
77 metastatic colorectal cancer
78 method
79 microarray approach
80 nuclear CDX2 expression
81 overall survival
82 patient subgroups
83 patients
84 period
85 poor differentiation
86 poor disease-free survival
87 potential biomarkers
88 pre
89 prognostic biomarker
90 prognostic role
91 proportional hazards methods
92 purpose
93 recurrence
94 reduced expression
95 relapse
96 resection
97 respect
98 role
99 single center
100 status
101 subgroups
102 survival
103 survival of patients
104 test
105 time
106 tissue microarray approach
107 total
108 with
109 schema:name Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis
110 schema:pagination 980
111 schema:productId N286530c456784a37910bd080103f120e
112 Nc9571f6d034940cbb6bf3abfc00e7493
113 Nca44fd6057db4c5f9823d0d4dde58da1
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107664418
115 https://doi.org/10.1186/s12885-018-4902-8
116 schema:sdDatePublished 2022-09-02T16:02
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N4a527fc0f0194ece996d006f16e70c1b
119 schema:url https://doi.org/10.1186/s12885-018-4902-8
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N016dd0f355ac4275b768ac623330ebfe schema:volumeNumber 18
124 rdf:type schema:PublicationVolume
125 N286530c456784a37910bd080103f120e schema:name dimensions_id
126 schema:value pub.1107664418
127 rdf:type schema:PropertyValue
128 N2f1f5330e2194b0db5ea732139505921 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Metastasectomy
130 rdf:type schema:DefinedTerm
131 N329b923deb494fee8d2f619640cc3582 rdf:first sg:person.0626665021.66
132 rdf:rest Na4ff9a21f88a4f14b78d6bdc26a0a683
133 N4a527fc0f0194ece996d006f16e70c1b schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 N4f59f382b6a3452fbb7f5f0df8b731b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Middle Aged
137 rdf:type schema:DefinedTerm
138 N58ae4b6928124edc91c5cd8a1535316d rdf:first sg:person.014277231772.83
139 rdf:rest N329b923deb494fee8d2f619640cc3582
140 N62612e52daae439aadd084914c338d0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Colorectal Neoplasms
142 rdf:type schema:DefinedTerm
143 N653e90f560d247348ca5a189990f317e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Neoplasm Recurrence, Local
145 rdf:type schema:DefinedTerm
146 N67d513dda6b84af3a3a73550bb683cb5 rdf:first sg:person.01324616107.44
147 rdf:rest rdf:nil
148 N6b03a7a706d942d8bf9b2bb3280d7c39 rdf:first sg:person.01052642300.03
149 rdf:rest Nbffee4206cfb4bb5ae96f215138d9ba3
150 N72ea159660c448e2874e519436af22b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name CDX2 Transcription Factor
152 rdf:type schema:DefinedTerm
153 N7309e7c6dfca4b95979c88e75c45d62c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Biomarkers, Tumor
155 rdf:type schema:DefinedTerm
156 N978942676a7447809a9b65ebcc06b7ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Liver Neoplasms
158 rdf:type schema:DefinedTerm
159 N9e9e9a18b14a44c8bd39a08e9b3e8b13 rdf:first sg:person.0767161400.15
160 rdf:rest Nebd0da50b1994513a6704f04a9ee81d1
161 Na4ff9a21f88a4f14b78d6bdc26a0a683 rdf:first sg:person.0612301703.87
162 rdf:rest N6b03a7a706d942d8bf9b2bb3280d7c39
163 Nb29ff4d3238e4a36b12236fe9da0d3ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Male
165 rdf:type schema:DefinedTerm
166 Nb5768e82639a4466b6857664220bb0a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Japan
168 rdf:type schema:DefinedTerm
169 Nbb73ec8c407d439a996200495f554b0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Treatment Outcome
171 rdf:type schema:DefinedTerm
172 Nbd5f936222604af49da011884bbc5f77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Humans
174 rdf:type schema:DefinedTerm
175 Nbecb89c64bbe4f3599ef0aabe09eb08a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Adult
177 rdf:type schema:DefinedTerm
178 Nbffee4206cfb4bb5ae96f215138d9ba3 rdf:first sg:person.011721243162.37
179 rdf:rest N67d513dda6b84af3a3a73550bb683cb5
180 Nc9571f6d034940cbb6bf3abfc00e7493 schema:name doi
181 schema:value 10.1186/s12885-018-4902-8
182 rdf:type schema:PropertyValue
183 Nca44fd6057db4c5f9823d0d4dde58da1 schema:name pubmed_id
184 schema:value 30326864
185 rdf:type schema:PropertyValue
186 Nca8624a60ffa4e1ba48aa809f2d420ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Female
188 rdf:type schema:DefinedTerm
189 Ne1677b3f9f344de681651dc0c6a8d0d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Aged
191 rdf:type schema:DefinedTerm
192 Ne570829994a841609a809b1f485461eb schema:issueNumber 1
193 rdf:type schema:PublicationIssue
194 Nebd0da50b1994513a6704f04a9ee81d1 rdf:first sg:person.0604174351.55
195 rdf:rest N58ae4b6928124edc91c5cd8a1535316d
196 Nf6678cc2f03046c5a1eb0177c999a231 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Drug Therapy
198 rdf:type schema:DefinedTerm
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
203 schema:name Oncology and Carcinogenesis
204 rdf:type schema:DefinedTerm
205 sg:grant.5933981 http://pending.schema.org/fundedItem sg:pub.10.1186/s12885-018-4902-8
206 rdf:type schema:MonetaryGrant
207 sg:journal.1024632 schema:issn 1471-2407
208 schema:name BMC Cancer
209 schema:publisher Springer Nature
210 rdf:type schema:Periodical
211 sg:person.01052642300.03 schema:affiliation grid-institutes:grid.486756.e
212 schema:familyName Ishikawa
213 schema:givenName Yuichi
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052642300.03
215 rdf:type schema:Person
216 sg:person.011721243162.37 schema:affiliation grid-institutes:grid.410807.a
217 schema:familyName Takahashi
218 schema:givenName Shunji
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011721243162.37
220 rdf:type schema:Person
221 sg:person.01324616107.44 schema:affiliation grid-institutes:grid.416695.9
222 schema:familyName Kanda
223 schema:givenName Hiroaki
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324616107.44
225 rdf:type schema:Person
226 sg:person.014277231772.83 schema:affiliation grid-institutes:grid.486756.e
227 schema:familyName Yamamoto
228 schema:givenName Noriko
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014277231772.83
230 rdf:type schema:Person
231 sg:person.0604174351.55 schema:affiliation grid-institutes:grid.486756.e
232 schema:familyName Inamura
233 schema:givenName Kentaro
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604174351.55
235 rdf:type schema:Person
236 sg:person.0612301703.87 schema:affiliation grid-institutes:grid.410807.a
237 schema:familyName Saiura
238 schema:givenName Akio
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612301703.87
240 rdf:type schema:Person
241 sg:person.0626665021.66 schema:affiliation grid-institutes:grid.410807.a
242 schema:familyName Mise
243 schema:givenName Yoshihiro
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626665021.66
245 rdf:type schema:Person
246 sg:person.0767161400.15 schema:affiliation grid-institutes:grid.486756.e
247 schema:familyName Shigematsu
248 schema:givenName Yasuyuki
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767161400.15
250 rdf:type schema:Person
251 sg:pub.10.1007/s00428-003-0833-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1013669468
252 https://doi.org/10.1007/s00428-003-0833-z
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s10147-012-0422-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009676145
255 https://doi.org/10.1007/s10147-012-0422-8
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/modpathol.2008.117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048766298
258 https://doi.org/10.1038/modpathol.2008.117
259 rdf:type schema:CreativeWork
260 sg:pub.10.1245/s10434-006-9018-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018471158
261 https://doi.org/10.1245/s10434-006-9018-8
262 rdf:type schema:CreativeWork
263 sg:pub.10.1245/s10434-010-0985-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033481932
264 https://doi.org/10.1245/s10434-010-0985-4
265 rdf:type schema:CreativeWork
266 grid-institutes:grid.410807.a schema:alternateName Division of Gastroenterology Center, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
267 Division of General Oncology, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
268 schema:name Division of Gastroenterology Center, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
269 Division of General Oncology, The Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
270 rdf:type schema:Organization
271 grid-institutes:grid.416695.9 schema:alternateName Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, 362-0806, Saitama, Japan
272 schema:name Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, 362-0806, Saitama, Japan
273 Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
274 rdf:type schema:Organization
275 grid-institutes:grid.486756.e schema:alternateName Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
276 schema:name Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto, 135-8550, Tokyo, Japan
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...